<DOC>
	<DOCNO>NCT02259647</DOCNO>
	<brief_summary>60 patient radiological , biopsy proven advanced HCC ( Hepatocellular carcinoma ) patient randomize two group . Cases group receive Sorafenib plus vitamin K control group receive Sorafenib plus placebo</brief_summary>
	<brief_title>Sorafenib Plus Vitamin K1 Versus Sorafenib Advanced Hepatocellular Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Vitamin K</mesh_term>
	<mesh_term>Vitamin K 1</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<criteria>Age 18 70 year Child A B cirrhosis hepatocellular carcinoma Biochemical , Radiological , histological evidence advance hepatocellular carcinoma diagnose stage C stage serum bilirubin &lt; 5 mg/dl accord BCLC staging system HCC portal vein thrombosis Unresectable cancer , assess carefully individual expert No recent active treatment like surgery , radiofrequency ablation , trans arterial chemo embolization , radiotherapy , chemotherapy ( within past 6 month ) Patients endstage hepatocellular carcinoma ( Stage D , BCLC ) poor performance status Child C cirrhosis HCC ( Hepatocellular carcinoma ) HCC acute decompensated state CLD GI bleed , increased jaundice , HE , SBP ( Spontaneous Bacterial Peritonitis ) Acute febrile illness Pregnancy lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>